Literature DB >> 23845873

Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor.

Chen Wang1, Hong-Yu Li, Bin Liu, Sheng Huang, Li Wu, Ying-Yi Li.   

Abstract

BACKGROUND: As one of the most lethal cancers, pancreatic cancer presents poor prognosis with an overall 5-y survival of less than 5%. We previously reported that Pim-3, a member of the proto-oncogene Pim family that encodes serine/threonine kinases, is aberrantly expressed in human pancreatic cancer lesions. In the current study, we investigated the role of Pim-3 in promoting tumor growth and angiogenesis in an orthotopic nude mouse model of human pancreatic cancer.
METHODS: We constructed retroviral vectors for human Pim-3 and a kinase-dead mutant of human Pim-3 (K69M); the retroviral supernatants generated from these vectors were then used to infect the human pancreatic cancer cell line MiaPaCa-2 to establish stable cell lines. We assessed cell proliferation using CCK-8, tumor growth, and angiogenesis in vivo in an orthotopic mouse model of pancreatic cancer. While tumor size was measured using magnetic resonance imaging, the tumor tissues were excised for protein extraction and histological analysis to detect vascular endothelium growth factor (VEGF) expression and vessel density.
RESULTS: We established an orthotopic nude mouse model of human pancreatic cancer. We observed that Pim-3 promoted the proliferation of human pancreatic cancer cells, both in vitro and in vivo. Moreover, Pim-3 is required for vasculogenesis of primary human pancreatic tumors in vivo and promotion of angiogenesis through the induction of VEGF expression.
CONCLUSIONS: Pim-3 can promote tumor growth and angiogenesis by stimulating the VEGF pathway.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nude mice orthotopic model; Pim-3; VEGF

Mesh:

Substances:

Year:  2013        PMID: 23845873     DOI: 10.1016/j.jss.2013.06.004

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.

Authors:  Weihua Chang; Menggang Liu; Jianhua Xu; Hangwei Fu; Bo Zhou; Tao Yuan; Ping Chen
Journal:  Tumour Biol       Date:  2016-09-16

2.  Serine threonine kinase Pim-3 regulates STAT3 pathway to inhibit proliferation of human liver cancers.

Authors:  Jianqiang Wang; Lijun Lao; Hui Zhao; Yuan Huang
Journal:  Int J Clin Exp Med       Date:  2014-02-15

Review 3.  Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.

Authors:  Ying-Yi Li; Naofumi Mukaida
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

4.  PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.

Authors:  Jianwei Xu; Guangbing Xiong; Zhe Cao; Hua Huang; Tianxiao Wang; Lei You; Li Zhou; Lianfang Zheng; Ya Hu; Taiping Zhang; Yupei Zhao
Journal:  J Exp Clin Cancer Res       Date:  2016-09-05

5.  Pim-3 Regulates Stemness of Pancreatic Cancer Cells via Activating STAT3 Signaling Pathway.

Authors:  Ting Li; Zhen Wang; Yi-Feng Hou; Ying-Yi Li
Journal:  J Cancer       Date:  2017-06-02       Impact factor: 4.207

6.  Pim-3 alleviates lipopolysaccharide-stimulated AR42J pancreatic acinar cell injury via improving the inflammatory microenvironment.

Authors:  Jie Jian; Shuang Li; Nian Fang; You-Zhao Cao; Li Zhen; Jian-Bin Qin; Bin Li
Journal:  Exp Ther Med       Date:  2019-10-10       Impact factor: 2.447

7.  Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.

Authors:  Yanchun Qu; Changwen Zhang; E Du; Andi Wang; Yuming Yang; Jianing Guo; Aixiang Wang; Zhihong Zhang; Yong Xu
Journal:  Med Sci Monit       Date:  2016-11-09

8.  Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors.

Authors:  Andrea L Casillas; Shailender S Chauhan; Rachel K Toth; Alva G Sainz; Amber N Clements; Corbin C Jensen; Paul R Langlais; Cindy K Miranti; Anne E Cress; Noel A Warfel
Journal:  Oncogene       Date:  2021-07-02       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.